Educational CME accredited programme

Frederick Raal

JohannesburgSouth Africa

Professor Raal is currently Professor and Head of the Division of Endocrinology and Metabolism, as well as Director of the Carbohydrate and Lipid Metabolism Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
He has authored or co-authored over 300 original articles and book chapters and has reviewed for several international journals including the New England Journal of Medicine, the Lancet, Circulation, and Atherosclerosis. He is on the Editorial Board of Atherosclerosis and is a Board member of the International Atherosclerosis Society.
Professor Raal is particularly interested in lipids and lipid disorders and has been integrally involved in the management of familial dyslipidaemia, particularly heterozygous and homozygous familial hypercholesterolaemia (FH). The major focus of his research remains the clinical, biochemical, genetic and therapeutic management of this condition and he continues to conduct studies with novel therapies such as PCSK9-inhibitors and ANGPTL3-inhibitors in this patient group.

Kausik Ray

LondonUnited Kingdom

Kausik Ray is currently Professor of Public Health, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London, Consultant Cardiologist and Chief Clinical Officer and Head of Trials –Discover Now as well as NIHR ARC National Lead of Cardiovascular Disease. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a post-doctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and President of the European Atherosclerosis Society, also serving on the EAS Consensus panel and EAS Executive Committee. Professor Ray has either been the National Lead Investigator, Principal Investigator, or served on committees for several major medical trials, as well as international registries and is currently involved in 8 ongoing trials in lipids and diabetes and the PI for ORION 1, 3, 11 assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS.
Professor Ray’s research interests have focused on the prevention of coronary disease with a focus on lipids, diabetes, biomarkers and risk prediction. He has an H index of 87, an i10 of 220 and over 92,000 citations for his work in journals such as New England Journal of Medicine, The Lancet, JAMA, European Heart Journal, Circulation and JACC. He has also been included in the Clarivate Analytics’ list of the top 1% most cited authors in all of global medicine in 2018, 2019 and 2020. Key original contributions which have influenced European and American guidelines include demonstrating the early benefits of statin therapy post ACS, the impact of more/less intensive glycaemic control on CVD and the risks/benefits of aspirin therapy in primary prevention. Recently, his work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. Currently Professor Ray leads the EAS FH Studies collaboration which is the first global registry of FH which includes 70 countries and 62,000 cases, as well as being the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.

Francois Mach

GenevaSwitzerland

Prof. François Mach is full Professor of cardiology at Geneva University Hospital and head of Cardiology Department since 2006. He completed a post-doctoral fellowship in the laboratory of Prof. Peter Libby, Brigham and Women’s Hospital, Boston (1995-1999). Between 2012-14, he was the President of the Swiss Society of Cardiology. He is the author of more than 500 high impact factor publications. As director of the atherosclerosis basic science laboratory, he and his research group have substantially contributed to a better clarification of the inflammatory mechanisms underlying atherosclerosis and its acute complications, both in human cohorts and animal studies. For several years now, he has also been strongly implicated in clinical research in the field of prevention, especially lipidology, by contributing to the design and completion of several clinical research projects and multi-center studies. He is also responsible of several Swiss cohorts of atherothrombotic patients, and is one of the 3 co-chairs of the ESC/EAS 2019 Lipid Guidelines, as well as co-chair of the ESC 2021 Prevention Guidelines.

Heinz Drexel

FeldkirchAustria

1983-1987 Assistant Professor, leading physician of the Diabetes inpatient and outpatient clinic, University of Innsbruck.
1988-1990 Associate Professor of Internal Medicine; 1991-1994 Head of Lipid Research. Division of Cardiology, University Hospital Zurich, Switzerland.
Since 1994 Professor of Medicine.
1994–2016 Head of Department of Medicine, County Hospital of Feldkirch, Austria.
Since 1997: Head of the Vorarlberg Institute for Vascular Investigation and Treatment, Austria
2006-2021 Dean of the Medical Faculty and Full Professor of Medicine, Private University of the Principality of Liechtenstein.
2007 Honorary Degree Doctor of Letters, Drexel University College of Medicine.
2009 Adjunct Professor of Medicine, Drexel University College of Medicine.
September 2017–December 2019 Senior Consultant, Division of Angiology, Swiss Cardiovascular Center, University Hospital Bern, Switzerland.
2018-2020 President of the ESC-Working Group “Cardiovascular Pharmacotherapy”.
Since December 2020 Head of the Department of Internal Medicine & Intensive Care, County Hospital Bregenz, Austria.
Experiences in Clinical Studies over 33 years.

Kausik Ray

LondonUnited Kingdom

Kausik Ray is currently Professor of Public Health, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London, Consultant Cardiologist and Chief Clinical Officer and Head of Trials –Discover Now as well as NIHR ARC National Lead of Cardiovascular Disease. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a post-doctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and President of the European Atherosclerosis Society, also serving on the EAS Consensus panel and EAS Executive Committee. Professor Ray has either been the National Lead Investigator, Principal Investigator, or served on committees for several major medical trials, as well as international registries and is currently involved in 8 ongoing trials in lipids and diabetes and the PI for ORION 1, 3, 11 assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS.
Professor Ray’s research interests have focused on the prevention of coronary disease with a focus on lipids, diabetes, biomarkers and risk prediction. He has an H index of 87, an i10 of 220 and over 92,000 citations for his work in journals such as New England Journal of Medicine, The Lancet, JAMA, European Heart Journal, Circulation and JACC. He has also been included in the Clarivate Analytics’ list of the top 1% most cited authors in all of global medicine in 2018, 2019 and 2020. Key original contributions which have influenced European and American guidelines include demonstrating the early benefits of statin therapy post ACS, the impact of more/less intensive glycaemic control on CVD and the risks/benefits of aspirin therapy in primary prevention. Recently, his work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. Currently Professor Ray leads the EAS FH Studies collaboration which is the first global registry of FH which includes 70 countries and 62,000 cases, as well as being the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.

Philippe Gabriel Steg

ParisFrance

– Chief, Department of Cardiology, Hôpital Bichat, Paris, France.
– Vice President for research of the board of the Assistance Publique-Hôpitaux de Paris network.
– Professor of Cardiology at Université de Paris.
– Chair of the FACT (French Alliance for cardiovascular Clinical Trials) academic research network.
Dr Steg has experience as a clinical trialist in coronary artery disease, diabetes and antithrombotics and has authored > 1 000 peer-reviewed articles. His H-Index is 116 and he has > 76 000 citations. He has been ”highly cited researcher” every year since 2014. He is Senior Associate Editor for Circulation.

Lale Tokgözoğlu

AnkaraTurkey

S. Lale Tokgözoğlu, MD, FACC, FESC is Professor of Cardiology at Hacettepe University, Ankara, Turkey. She is currently the immediate Past-President of the European Atherosclerosis Society and Deputy Editor of the European Heart Journal. She chaired the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010. Prof.  Tokgözoğlu has served on the Board of the Turkish Society of Cardiology and was elected to be the first female President of the Society in its history, between 2014-2016. During that time, she worked with the Ministry of Health to develop ‘Heart Health policies’ and strategies. She also chaired the Dyslipidaemia Working Group of the Turkish Society of Cardiology. She has contributed to several Guidelines and Consensus Papers on dyslipidaemia and Preventive Cardiology both in Europe and nationally. She was a member of the Steering Committee of the EUROASPIRE III-V studies which were the landmark studies defining preventive measures in Europe. She has also served on the Board of the Prevention Association as well as different committees of the European Society of Cardiology including the Fellowship and Training Committee, the Education Committee and currently the Research and Grants Committee. She is a member of the Science Academy and a founding member of the Atherosclerosis Research and Education Society in Turkey. She is also a founding member of the Department of Noncommunicable diseases in Hacettepe University. She serves on the Scientific and Research Council of Turkey Working Group on women researchers.

Awards:

Metrodora Award Global Leader in Science and Health 2020

Istanbul Medical Association Science Award in 2019

Paul Dudley White Science team award AHA 2017

Prof. Dr. Şeref Zileli Resident of the Year” Award in 1987

Young Investigator Award of the Turkish Society of Cardiology in 1994

Kausik Ray

LondonUnited Kingdom

Kausik Ray is currently Professor of Public Health, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London, Consultant Cardiologist and Chief Clinical Officer and Head of Trials –Discover Now as well as NIHR ARC National Lead of Cardiovascular Disease. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a post-doctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and President of the European Atherosclerosis Society, also serving on the EAS Consensus panel and EAS Executive Committee. Professor Ray has either been the National Lead Investigator, Principal Investigator, or served on committees for several major medical trials, as well as international registries and is currently involved in 8 ongoing trials in lipids and diabetes and the PI for ORION 1, 3, 11 assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS.
Professor Ray’s research interests have focused on the prevention of coronary disease with a focus on lipids, diabetes, biomarkers and risk prediction. He has an H index of 87, an i10 of 220 and over 92,000 citations for his work in journals such as New England Journal of Medicine, The Lancet, JAMA, European Heart Journal, Circulation and JACC. He has also been included in the Clarivate Analytics’ list of the top 1% most cited authors in all of global medicine in 2018, 2019 and 2020. Key original contributions which have influenced European and American guidelines include demonstrating the early benefits of statin therapy post ACS, the impact of more/less intensive glycaemic control on CVD and the risks/benefits of aspirin therapy in primary prevention. Recently, his work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. Currently Professor Ray leads the EAS FH Studies collaboration which is the first global registry of FH which includes 70 countries and 62,000 cases, as well as being the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.

Marcello Arca

CataniaItaly

University of Rome Sapienza. He completed his research training as postdoctoral fellow at the Center for Human Nutrition and then at the Department of Molecular Genetics, at the UT Southwestern Medical Center in Dallas, Texas (USA). He is full professor of Internal Medicine and, at present, he Chair of the Department of Translational and Precision Medicine: He is also the Director the Unit of Internal Medicine and Metabolic Diseases as well as the Unit of Rare Lipid Disorders at the University Hospital Policlinico Umberto I in Rome.
The research interests of Prof. Arca are related to genetic disorders of lipid metabolism, to genetics of atherosclerosis and to treatment of cardiovascular risk. He is co-authors of 300 papers in peer reviewed journal and 10 chapters of books. He is member of the Editorial Board of Endocrine and American Journal of Preventive Medicine and he is serving as reviewer for several scientific journals in the area of metabolism, cardiovascular disease, genetics and internal medicine. At present, he is holding the chair of President of the Italian Society of Atherosclerosis (SISA)

Kausik Ray

LondonUnited Kingdom

Kausik Ray is currently Professor of Public Health, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London, Consultant Cardiologist and Chief Clinical Officer and Head of Trials –Discover Now as well as NIHR ARC National Lead of Cardiovascular Disease. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a post-doctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and President of the European Atherosclerosis Society, also serving on the EAS Consensus panel and EAS Executive Committee. Professor Ray has either been the National Lead Investigator, Principal Investigator, or served on committees for several major medical trials, as well as international registries and is currently involved in 8 ongoing trials in lipids and diabetes and the PI for ORION 1, 3, 11 assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS.
Professor Ray’s research interests have focused on the prevention of coronary disease with a focus on lipids, diabetes, biomarkers and risk prediction. He has an H index of 87, an i10 of 220 and over 92,000 citations for his work in journals such as New England Journal of Medicine, The Lancet, JAMA, European Heart Journal, Circulation and JACC. He has also been included in the Clarivate Analytics’ list of the top 1% most cited authors in all of global medicine in 2018, 2019 and 2020. Key original contributions which have influenced European and American guidelines include demonstrating the early benefits of statin therapy post ACS, the impact of more/less intensive glycaemic control on CVD and the risks/benefits of aspirin therapy in primary prevention. Recently, his work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. Currently Professor Ray leads the EAS FH Studies collaboration which is the first global registry of FH which includes 70 countries and 62,000 cases, as well as being the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.

Lale Tokgözoğlu

AnkaraTurkey

S. Lale Tokgözoğlu, MD, FACC, FESC is Professor of Cardiology at Hacettepe University, Ankara, Turkey. She is currently the immediate Past-President of the European Atherosclerosis Society and Deputy Editor of the European Heart Journal. She chaired the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010. Prof.  Tokgözoğlu has served on the Board of the Turkish Society of Cardiology and was elected to be the first female President of the Society in its history, between 2014-2016. During that time, she worked with the Ministry of Health to develop ‘Heart Health policies’ and strategies. She also chaired the Dyslipidaemia Working Group of the Turkish Society of Cardiology. She has contributed to several Guidelines and Consensus Papers on dyslipidaemia and Preventive Cardiology both in Europe and nationally. She was a member of the Steering Committee of the EUROASPIRE III-V studies which were the landmark studies defining preventive measures in Europe. She has also served on the Board of the Prevention Association as well as different committees of the European Society of Cardiology including the Fellowship and Training Committee, the Education Committee and currently the Research and Grants Committee. She is a member of the Science Academy and a founding member of the Atherosclerosis Research and Education Society in Turkey. She is also a founding member of the Department of Noncommunicable diseases in Hacettepe University. She serves on the Scientific and Research Council of Turkey Working Group on women researchers.

Awards:

Metrodora Award Global Leader in Science and Health 2020

Istanbul Medical Association Science Award in 2019

Paul Dudley White Science team award AHA 2017

Prof. Dr. Şeref Zileli Resident of the Year” Award in 1987

Young Investigator Award of the Turkish Society of Cardiology in 1994

Carlos Escobar Cervantes

MadridSpain

MD graduate at the Universidad Autonoma de Madrid (1993-99). PhD grade at the Universidad de Alcalá; Doctoral Thesis qualification: A cum laude, unanimously (2007). Consultant cardiologist at the University Hospital La Paz (Madrid).
Past-member of the Executive Committee of the Investigation Agency of the Spanish Society of Cardiology. Past-president of the Clinical Cardiology group of the Spanish Society of Cardiology. Member of the European Society of Cardiology (ESC). Member of the Cardiovascular Pharmacology and Drug Therapy Working Group of ESC. Member of the Council of Cardio-Oncology Regular of ESC. Member of the Council of Stroke Regular of ESC. Member of the Spanish Society of Cardiology. Member of the International Lipid Expert Panel. Member of the working group of hypertension and cardiovascular disease of SEMERGEN (Spain).
Referee of several national and international peer-review journals. Participation in several clinical trials and investigation projects in the fields of hypertension, heart failure, atrial fibrillation, acute coronary syndrome, pulmonary embolism and cardiometabolic disease.
Over 375 papers published in national and international peer-review journals and over 60 chapters in Cardiology textbooks.

Maciej Banach

LodzPoland

Prof. Maciej Banach was an Undersecretary of State at the Ministry of Science and Higher Education of the Republic of Poland (2010-2012), and a President of the Polish Mother’s Memorial Hospital – Research Institute (PMMHRI) (February 2014-March 2021). He is a Head of Cardiovascular Research Centre at University of Zielona Gora, full Professor of Cardiology at the Medical University of Lodz (MUL) and PMMHRI, Head of Foreign Affairs Office (2012-2014), Head of Department of Preventive Cardiology and Lipidology at the Medical University of Lodz and Professor in the Department of Nephrology, Hypertension and Family Medicine, Chair of Nephrology and Hypertension, at the WAM University Hospital in Lodz, Poland (2009-).

He is a Secretary of the European Atherosclerosis Society (EAS) (2021-2024) and member of the Scientific and Health Policy Advisory Group of the FH Europe. He is a Founder and Head of the Polish Lipid Association (PoLA) (2011-) and Lodz Chapter of Polish Society of Hypertension (2009-). He is the founder of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC; lbpmcgroup.umed.pl) Group (2012-) – a group of over 150 worldwide experts aimed to investigate the most important issues in the field of lipid disorders, hypertension, nutrition and cardiovascular risk, as well as the International Lipid Expert Panel (ILEP; ilep.eu) (2015-), currently with >50 national society members, which has been founded to prepare recommendations in the area of preventive cardiology in the most debatable issues that have not been covered in the existing guidelines. He is also a member of the REPROGRAM Consortium – a group of experts challenging with Covid-19 pandemic, member of 2 largest worldwide databases – the Global Burden of Disease (GDB) (University of Washington, Seattle, US) and Non-Communicable Diseases Risk Factor Collaboration (NCD-RisC, Imperial College of London, UK). He is also Founder and President of the foundation – Think-Tank “Innovation for Health”, which gathers six main health research institutes and over 40 medical business representatives in Poland with main aim to make innovations in the medical area in Poland. He is a Visiting Professor of University of Alabama at Birmingham (UAB) and University of Medicine and Pharmacy Victor Babes in Timisoara, Romania, and University of California at Irvine.

Prof. Banach has published over 1000 original articles, reviews, editorials, and book chapters in the field of hypertension, dyslipidemia, cardiology, and risk stratification. His combined IF (for only full-text manuscripts) is over 10,000 pts, number of citations: 39,090 (acc. Web of Science Core Collection/Publons with >14,000 citations for year 2021), 40,228 (acc. SCOPUS; with >15,000 citations for year 2021), 49,601 (acc. ResearchGate), and 59,898 (acc. Google Scholar; with >21,000 citations for year 2021), Hirsch’s Index = 75 (WoS/Publons), 75 (SCOPUS), 88 (ResearchGate) and 93 (i10-index: 598) (Google Scholar) – being within 1% the highest cited scientists in the world (in the research area of Clinical Medicine and Pharmacology and Toxicology) according to Essential Science Indicators by Clarivate (with 42 TOP Papers). Prof. Banach is also within top 10 worldwide experts according to ExpertScape in the field of lipids (9), statins (2), dyslipidemias (6), cholesterol (5), lipoproteins (12), LDL cholesterol (9), lipoproteins LDL (6), HDL cholesterol (5), and dietary supplements (15). He is also a 1% Top Reviewer in the areas of Clinical Medicine and Cross-Field (in 2018 and 2019) by Publons/Clarivate and Publons Academy Mentor.

He is Founder (2005) and Editor-in-Chief of the Archives of Medical Science (IF2020 = 3.318), Archives of Medical Science – Civilization Diseases, and Archives of Medical Science – Atherosclerotic Diseases, Deputy Editor of European Heart Journal Open, Editor in Chief of the Cardiology Section in Journal of Clinical Medicine, Section Editor of Current Atherosclerosis Reports, Scientific Coordinator of the HeartBeat Journal (2012-2018), Regional Associate Editor of European Heart Journal – Quality of Care and Clinical Outcomes, Co-Founder and Deputy Editor of Thyroid Research (2007-2012), Associate/Section Editor of BMC Medicine, Scientific Reports, Recent Patents on Cardiovascular Drugs Discovery & Biomed Research International, and member of Editorial Advisory Board of over 60 international medical journals. Guest Editor (2010-) among others in BMC Medicine, Expert Opinion on Pharmacotherapy, Nutrients, Current Hypertension Reports, Journal of Diabetes Research, Current Vascular Pharmacology, Current Pharmaceutical Design, Current Medicinal Chemistry and Frontiers in Digital Public. He is also a Faculty member of F1000 prime. He is Reviewer of over 80 international journals, including New England Journal of Medicine, European Heart Journal, JACC, Circulation, JAMA-Cardiology, JAMA Network Open, Lancet Diabetes & Endocrinology, Circulation Research, and British Medical Journal; editor or author of 31 books (102 chapters). He was also a Scientific President (2016-2020) of the Termedia Publishing House, being responsible for the indexation and developing of over 50 scientific journals, including 9 journals with IF.

Participation in clinical trials since 2005: (1) IPDACS Trial (Incidence and Predictors of Delirium After Cardiac Surgery) (NCT00784576) (study coordinator [SC]); (2) ACT 2 Trial with RSD1235 – vernakalant (principal investigator [PI]); (3) The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle (NCT01015144) (PI); (4) SWEEP TRIAL (Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease) (PI); (5) SWEEP OLE Trial (PI); (6) STIPPARE Trial (Simvastatin in the Treatment of Isolated arterial hyPertension and Prevention of cARdiovascular Events) (NCT01017835) (PI); (7) FIRST Trial (Ferumoxytol Compared to Iron Sucrose Trial: A Randomized, Multicenter Trial of Ferumoxytol Compared to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects with Chronic Kidney Disease); (8) FER-CKD Trial (An open-label multicentre, randomised 3-arm study to investigate the comparative efficacy and safety of intravenous ferric carboxymaltose versus oral iron for the treatment of iron deficiency anaemia in subjects with non-dialysis-dependent chronic kidney disease) (Co-Investigator [CPI]); (9) FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk) trial (PI); (10) ENSURE-AF (national PI [NPI]); (10) BetOnMACE trial (RVX222-CS-015) (NPI); (11) ODDYSEY APPRISE Trial (LPS14245) (NPI); (12) CLEAR Harmony trial (Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk) (PI); (13) CLEAR Harmony OLE Trial (PI); (14) CLEAR Outcomes Study (1002-043) (NPI); (15) Da Vinci Study (co-NPI), ODDYSEY Kids (NPI), (16) VESALIUS-REAL Trial with evolocumab (NPI), (17) LIPIDOGRAM & LIPIDOGEN study (co-PI), (18) FHSC Registry (NPI), (19) TERCET Registry; (20) VESALIUS-CV Trial with evolocumab (PI), and (21) Lp(a)HORIZON with TQJ231 (PI), (22) ORION-16 with inclisiran (PI), (23) Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia (PI).

He is a fellow of the Council for High Blood Pressure Research of the American Heart Association (FAHA), National Lipid Association (FNLA), American Society of Angiology (FASA), European Society of Cardiology (FESC), Royal Society for Public Health (FRSPH) and Society of Geriatric Cardiology (FSGC; 2008-2010). He is a member of the working-core of Alliance for Biomedical Research/European Council for Health Research (2011-2013 and 2016- being as a EAS representative), steering committee of European Innovation Partnership in Active and Healthy Ageing (2010-2012) at the European Commission, member of the European Commission’s Scientific Panel for Health (SPH) (2014-2017), and steering committee of Centre for Good Aging / Healthy Ageing Research Center (HARC) at the Medical University of Lodz, member of Committee for Public Health of the Polish Academy of Sciences, member of the Scientific Board of Institute of Sport in Warsaw, Poland, and the Presiding Board of Scientific Committee of the Polish Ministry of Health (2015-). He is an expert of the European Medicines Agency (EMA, 2018-), and member of prestigious EU Academy of Sciences (EUAS; 2018-).

He is a laureate of several prizes and award, including: Doctor Honoris Causa of the Medical University in Kosice, Slovak Republic (2020), on Top-100 List of the most influential scientists in medicine in Poland for year 2020 (position 8), 2019 (10), and 2018 (9), Doctor Honoris Causa of the Carol Davila University of Medicine and Pharmacy in Bucharest, Romania, “Gold Scalpel” Distinction in 2019 for the Innovation (Smart Hospital); Honorary Member of the Romanian Society of Cardiology (2019), Doctor Honoris Causa of the Institute of Cardiology in Kiev (2018), and the University of Medicine and Pharmacy Victor Babes in Timisoara (2017); Gold Honorary Medal for scientific achievements of the Medical Faculty of Medical University in Kosice, Slovak Republic (2018), The Manager of the Year 2016 – Public Entities (2017), “Innovator of the Year – Science Category” by Wprost journal (2017); “Gold Scalpel” Distinction in 2016 for the Innovation; The Personality of the Year 2013 in Poland for the development of science in the field of healthcare – founded by the Heath Manager journal (Termedia Publishing House), Super-Talent in Medicine 2012 Award – the winner of the competition for young scientists in medicine (up to 40) founded by Puls Medycyny journal; scientific awards of Ministry of Health of Republic of Poland for the cycle of publications (2009, 2011), >40 individual and group scientific awards of President of Medical University of Lodz (2009-2020); START Award (2008) and Conferences Awards (2005, 2007) of Foundation for Polish Science, Polityka journal Awards for Young Scientists (2006), and Travel Grants of European Society of Hypertension (2007) and Heart Failure Association of ESC (2005, 2007).

His main area of scientific interests concerns hypertension aspects (risk stratification, prehypertension, new biomarkers, optimal level of BP – J-curve phenomenon, pharmacotherapy/combined therapy, prevention, complications), lipid disorders (risk stratification, new biomarkers, diagnosis, rare diseases), dyslipidemia therapy (statins, new drugs, combined treatment) and new drugs in CVD therapy.

Maciej Banach

LodzPoland

Prof. Maciej Banach was an Undersecretary of State at the Ministry of Science and Higher Education of the Republic of Poland (2010-2012), and a President of the Polish Mother’s Memorial Hospital – Research Institute (PMMHRI) (February 2014-March 2021). He is a Head of Cardiovascular Research Centre at University of Zielona Gora, full Professor of Cardiology at the Medical University of Lodz (MUL) and PMMHRI, Head of Foreign Affairs Office (2012-2014), Head of Department of Preventive Cardiology and Lipidology at the Medical University of Lodz and Professor in the Department of Nephrology, Hypertension and Family Medicine, Chair of Nephrology and Hypertension, at the WAM University Hospital in Lodz, Poland (2009-).

He is a Secretary of the European Atherosclerosis Society (EAS) (2021-2024) and member of the Scientific and Health Policy Advisory Group of the FH Europe. He is a Founder and Head of the Polish Lipid Association (PoLA) (2011-) and Lodz Chapter of Polish Society of Hypertension (2009-). He is the founder of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC; lbpmcgroup.umed.pl) Group (2012-) – a group of over 150 worldwide experts aimed to investigate the most important issues in the field of lipid disorders, hypertension, nutrition and cardiovascular risk, as well as the International Lipid Expert Panel (ILEP; ilep.eu) (2015-), currently with >50 national society members, which has been founded to prepare recommendations in the area of preventive cardiology in the most debatable issues that have not been covered in the existing guidelines. He is also a member of the REPROGRAM Consortium – a group of experts challenging with Covid-19 pandemic, member of 2 largest worldwide databases – the Global Burden of Disease (GDB) (University of Washington, Seattle, US) and Non-Communicable Diseases Risk Factor Collaboration (NCD-RisC, Imperial College of London, UK). He is also Founder and President of the foundation – Think-Tank “Innovation for Health”, which gathers six main health research institutes and over 40 medical business representatives in Poland with main aim to make innovations in the medical area in Poland. He is a Visiting Professor of University of Alabama at Birmingham (UAB) and University of Medicine and Pharmacy Victor Babes in Timisoara, Romania, and University of California at Irvine.

Prof. Banach has published over 1000 original articles, reviews, editorials, and book chapters in the field of hypertension, dyslipidemia, cardiology, and risk stratification. His combined IF (for only full-text manuscripts) is over 10,000 pts, number of citations: 39,090 (acc. Web of Science Core Collection/Publons with >14,000 citations for year 2021), 40,228 (acc. SCOPUS; with >15,000 citations for year 2021), 49,601 (acc. ResearchGate), and 59,898 (acc. Google Scholar; with >21,000 citations for year 2021), Hirsch’s Index = 75 (WoS/Publons), 75 (SCOPUS), 88 (ResearchGate) and 93 (i10-index: 598) (Google Scholar) – being within 1% the highest cited scientists in the world (in the research area of Clinical Medicine and Pharmacology and Toxicology) according to Essential Science Indicators by Clarivate (with 42 TOP Papers). Prof. Banach is also within top 10 worldwide experts according to ExpertScape in the field of lipids (9), statins (2), dyslipidemias (6), cholesterol (5), lipoproteins (12), LDL cholesterol (9), lipoproteins LDL (6), HDL cholesterol (5), and dietary supplements (15). He is also a 1% Top Reviewer in the areas of Clinical Medicine and Cross-Field (in 2018 and 2019) by Publons/Clarivate and Publons Academy Mentor.

He is Founder (2005) and Editor-in-Chief of the Archives of Medical Science (IF2020 = 3.318), Archives of Medical Science – Civilization Diseases, and Archives of Medical Science – Atherosclerotic Diseases, Deputy Editor of European Heart Journal Open, Editor in Chief of the Cardiology Section in Journal of Clinical Medicine, Section Editor of Current Atherosclerosis Reports, Scientific Coordinator of the HeartBeat Journal (2012-2018), Regional Associate Editor of European Heart Journal – Quality of Care and Clinical Outcomes, Co-Founder and Deputy Editor of Thyroid Research (2007-2012), Associate/Section Editor of BMC Medicine, Scientific Reports, Recent Patents on Cardiovascular Drugs Discovery & Biomed Research International, and member of Editorial Advisory Board of over 60 international medical journals. Guest Editor (2010-) among others in BMC Medicine, Expert Opinion on Pharmacotherapy, Nutrients, Current Hypertension Reports, Journal of Diabetes Research, Current Vascular Pharmacology, Current Pharmaceutical Design, Current Medicinal Chemistry and Frontiers in Digital Public. He is also a Faculty member of F1000 prime. He is Reviewer of over 80 international journals, including New England Journal of Medicine, European Heart Journal, JACC, Circulation, JAMA-Cardiology, JAMA Network Open, Lancet Diabetes & Endocrinology, Circulation Research, and British Medical Journal; editor or author of 31 books (102 chapters). He was also a Scientific President (2016-2020) of the Termedia Publishing House, being responsible for the indexation and developing of over 50 scientific journals, including 9 journals with IF.

Participation in clinical trials since 2005: (1) IPDACS Trial (Incidence and Predictors of Delirium After Cardiac Surgery) (NCT00784576) (study coordinator [SC]); (2) ACT 2 Trial with RSD1235 – vernakalant (principal investigator [PI]); (3) The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle (NCT01015144) (PI); (4) SWEEP TRIAL (Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease) (PI); (5) SWEEP OLE Trial (PI); (6) STIPPARE Trial (Simvastatin in the Treatment of Isolated arterial hyPertension and Prevention of cARdiovascular Events) (NCT01017835) (PI); (7) FIRST Trial (Ferumoxytol Compared to Iron Sucrose Trial: A Randomized, Multicenter Trial of Ferumoxytol Compared to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects with Chronic Kidney Disease); (8) FER-CKD Trial (An open-label multicentre, randomised 3-arm study to investigate the comparative efficacy and safety of intravenous ferric carboxymaltose versus oral iron for the treatment of iron deficiency anaemia in subjects with non-dialysis-dependent chronic kidney disease) (Co-Investigator [CPI]); (9) FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk) trial (PI); (10) ENSURE-AF (national PI [NPI]); (10) BetOnMACE trial (RVX222-CS-015) (NPI); (11) ODDYSEY APPRISE Trial (LPS14245) (NPI); (12) CLEAR Harmony trial (Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk) (PI); (13) CLEAR Harmony OLE Trial (PI); (14) CLEAR Outcomes Study (1002-043) (NPI); (15) Da Vinci Study (co-NPI), ODDYSEY Kids (NPI), (16) VESALIUS-REAL Trial with evolocumab (NPI), (17) LIPIDOGRAM & LIPIDOGEN study (co-PI), (18) FHSC Registry (NPI), (19) TERCET Registry; (20) VESALIUS-CV Trial with evolocumab (PI), and (21) Lp(a)HORIZON with TQJ231 (PI), (22) ORION-16 with inclisiran (PI), (23) Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia (PI).

He is a fellow of the Council for High Blood Pressure Research of the American Heart Association (FAHA), National Lipid Association (FNLA), American Society of Angiology (FASA), European Society of Cardiology (FESC), Royal Society for Public Health (FRSPH) and Society of Geriatric Cardiology (FSGC; 2008-2010). He is a member of the working-core of Alliance for Biomedical Research/European Council for Health Research (2011-2013 and 2016- being as a EAS representative), steering committee of European Innovation Partnership in Active and Healthy Ageing (2010-2012) at the European Commission, member of the European Commission’s Scientific Panel for Health (SPH) (2014-2017), and steering committee of Centre for Good Aging / Healthy Ageing Research Center (HARC) at the Medical University of Lodz, member of Committee for Public Health of the Polish Academy of Sciences, member of the Scientific Board of Institute of Sport in Warsaw, Poland, and the Presiding Board of Scientific Committee of the Polish Ministry of Health (2015-). He is an expert of the European Medicines Agency (EMA, 2018-), and member of prestigious EU Academy of Sciences (EUAS; 2018-).

He is a laureate of several prizes and award, including: Doctor Honoris Causa of the Medical University in Kosice, Slovak Republic (2020), on Top-100 List of the most influential scientists in medicine in Poland for year 2020 (position 8), 2019 (10), and 2018 (9), Doctor Honoris Causa of the Carol Davila University of Medicine and Pharmacy in Bucharest, Romania, “Gold Scalpel” Distinction in 2019 for the Innovation (Smart Hospital); Honorary Member of the Romanian Society of Cardiology (2019), Doctor Honoris Causa of the Institute of Cardiology in Kiev (2018), and the University of Medicine and Pharmacy Victor Babes in Timisoara (2017); Gold Honorary Medal for scientific achievements of the Medical Faculty of Medical University in Kosice, Slovak Republic (2018), The Manager of the Year 2016 – Public Entities (2017), “Innovator of the Year – Science Category” by Wprost journal (2017); “Gold Scalpel” Distinction in 2016 for the Innovation; The Personality of the Year 2013 in Poland for the development of science in the field of healthcare – founded by the Heath Manager journal (Termedia Publishing House), Super-Talent in Medicine 2012 Award – the winner of the competition for young scientists in medicine (up to 40) founded by Puls Medycyny journal; scientific awards of Ministry of Health of Republic of Poland for the cycle of publications (2009, 2011), >40 individual and group scientific awards of President of Medical University of Lodz (2009-2020); START Award (2008) and Conferences Awards (2005, 2007) of Foundation for Polish Science, Polityka journal Awards for Young Scientists (2006), and Travel Grants of European Society of Hypertension (2007) and Heart Failure Association of ESC (2005, 2007).

His main area of scientific interests concerns hypertension aspects (risk stratification, prehypertension, new biomarkers, optimal level of BP – J-curve phenomenon, pharmacotherapy/combined therapy, prevention, complications), lipid disorders (risk stratification, new biomarkers, diagnosis, rare diseases), dyslipidemia therapy (statins, new drugs, combined treatment) and new drugs in CVD therapy.

Michal Vrablik

Praha 2Czech Republic

Michal Vrablik M.D., Ph.D. is a Professor of Internal Medicine at the 1st Faculty of Medicine, Charles University in Prague, the Czech Republic. His main interests include preventive cardiology, clinical lipidology, CVD risk reduction strategies.
He is the chairman of the Czech Atherosclerosis Society, member of board of the Czech Society of Internal Medicine and the chairman of the Czech Association of Preventive Cardiology of the Czech Society of Cardiology. He is the head of the National centre of the FH screening MedPed program.
He served as a member of the Executive Committee of the European Atherosclerosis Society between 2012 and 2016.He closely cooperates with the International Atherosclerosis Society being the chair of IAS Regional Federation for Europe since January 2019. Since 2010 Dr. Vrablik has co-organized International Atherosclerosis Research School endorsed by the EAS and IAS.
Dr. Vrablik has authored and co-authored more than 400 papers in peer-reviewed scientific journals. He is the sole author of three monographs and of 25 book chapters. He is also a member of editorial board as well as a reviewer for several national and international journals.